Howard Capital Management (New York)’s iShares Biotechnology ETF IBB Stock Holding History

Howard Capital Management (New York)’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$7.27M	Sell	47,971 -560	-1%	-$80K	0.82%	33
2020 Q3	$6.57M	Sell	48,531 -4,250	-8%	-$577K	0.83%	33
2020 Q2	$7.21M	Sell	52,781 -30	-0.1%	-$3.82K	0.96%	32
2020 Q1	$5.69M	Sell	52,811 -3,995	-7%	-$460K	0.97%	31
2019 Q4	$6.85M	Sell	56,806 -1,259	-2%	-$140K	0.86%	36
2019 Q3	$5.78M	Buy	58,065 +275	+0.5%	+$28.8K	0.82%	35
2019 Q2	$6.3M	Sell	57,790 -1,575	-3%	-$168K	0.86%	36
2019 Q1	$6.64M	Sell	59,365 -4,465	-7%	-$490K	0.94%	36
2018 Q4	$6.16M	Sell	63,830 -915	-1%	-$97.1K	1.02%	34
2018 Q3	$7.89M	Sell	64,745 -464	-0.7%	-$54.6K	1.05%	38
2018 Q2	$7.16M	Sell	65,209 -125,430	-66%	-$13.4M	1.03%	38
2018 Q1	$20.3M	Sell	190,639 -18,215	-9%	-$2.02M	2.96%	7
2017 Q4	$22.3M	Sell	208,854 -873	-0.4%	-$93.3K	3.28%	6
2017 Q3	$23.3M	Buy	209,727 +2,535	+1%	+$271K	3.59%	4
2017 Q2	$21.4M	Buy	207,192 +3,555	+2%	+$350K	3.37%	5
2017 Q1	$19.9M	Buy	203,637 +4,890	+2%	+$468K	3.32%	5
2016 Q4	$17.6M	Buy	198,747 +4,251	+2%	+$387K	3.12%	6
2016 Q3	$18.8M	Buy	194,496 +933	+0.5%	+$88.8K	3.41%	4
2016 Q2	$16.6M	Buy	193,563 +2,730	+1%	+$245K	3.19%	5
2016 Q1	$16.6M	Buy	190,833 +525	+0.3%	+$46.9K	3.26%	7
2015 Q4	$21.5M	Buy	190,308 +660	+0.3%	+$71.6K	4.21%	2
2015 Q3	$19.2M	Sell	189,648 -2,157	-1%	-$259K	3.9%	2
2015 Q2	$23.6M	Sell	191,805 -6,495	-3%	-$778K	4.49%	2
2015 Q1	$22.7M	Sell	198,300 -36,759	-16%	-$4.05M	4.38%	2
2014 Q4	$23.8M	Sell	235,059 -11,340	-5%	-$1.1M	4.57%	1
2014 Q3	$22.5M	Sell	246,399 -3,240	-1%	-$284K	4.48%	1
2014 Q2	$21.4M	Sell	249,639 -9,711	-4%	-$765K	4.21%	1
2014 Q1	$20.4M	Buy	259,350 +6,975	+3%	+$581K	4.03%	1
2013 Q4	$19.1M	Buy	252,375 +2,010	+0.8%	+$143K	3.92%	1
2013 Q3	$17.5M	Buy	250,365 +2,418	+1%	+$158K	4.28%	1
2013 Q2	$14.4M	Buy	+247,947	New	+$14.3M	3.76%	2

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

Howard Capital Management (New York)'s IBB Position: Q4 2020 in Review

Howard Capital Management (New York) reduced its iShares Biotechnology ETF (IBB) stake by 1.2% in Q4 2020, selling an estimated $80K and leaving 47,971 shares worth $7.27M. The position accounts for 0.82% of the portfolio, ranked #33.

Howard Capital Management (New York) first reported a position in IBB in Q2 2013 and has held it in 31 quarters since. The position peaked at $23.8M in Q4 2014. 856 funds tracked by Wall St. Rank hold IBB as of Q4 2020.

Howard Capital Management (New York) held 47,971 shares of iShares Biotechnology ETF worth $7.27M as of Q4 2020.
Howard Capital Management (New York) sold 560 iShares Biotechnology ETF shares in Q4 2020, an estimated $80K.
iShares Biotechnology ETF made up 0.82% of Howard Capital Management (New York)'s portfolio in Q4 2020, its #33 holding.
Howard Capital Management (New York) first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 31 quarters since.
Howard Capital Management (New York)'s iShares Biotechnology ETF position peaked at $23.8M in Q4 2014.
856 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2020.

Based on Howard Capital Management (New York)'s 13F filing for Q4 2020, filed 2 Feb 2021.